Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Driven by 1 paper. Top paper: “Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN”.
Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn +22 more